Artiva Biotherapeutics, Inc. ARTV Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$23.52M-13.2% | -$20.77M+3.5% | -$21.53M-1.3% | -$21.25M-4.6% | -$20.31M-26.2% | ||
| $666K0.0% | $666K+0.6% | $662K+3.3% | $641K+2.1% | $628K+2.3% | ||
| $1.59M+0.3% | $1.59M-2.6% | $1.63M+5.3% | $1.55M-24.5% | $2.05M-6.0% | ||
| —— | $0— | $0— | $0— | $0+100% | ||
| $1.81M+1,308% | -$150K+66.1% | -$442K-111% | -$209K-610% | $41K— | ||
| -$4M-269% | $2.37M+111% | $1.12M+303% | -$550K+40.9% | -$931K+6.1% | ||
| —— | $40K-89.5% | $380K+1,420% | $25K+110% | -$254K-719% | ||
| -$67K-458% | -$12K— | —— | -$204K-332% | $88K— | ||
| -$20.95M-42.3% | -$14.73M+23.3% | -$19.2M+16.5% | -$22.98M-15.8% | -$19.84M-35.4% | ||
| $242K-42.5% | $421K-29.8% | $600K-43.1% | $1.06M+106% | $511K+698% | ||
| $6.44M-14.6% | $7.54M-40.8% | $12.75M+110% | $6.07M-67.2% | $18.52M+24.7% | ||
| $22M-8.3% | $24M-19.0% | $29.62M+4.9% | $28.25M-2.6% | $29M+108% | ||
| $15.32M-4.5% | $16.04M-1.5% | $16.28M-22.9% | $21.12M+112% | $9.97M+1,132% | ||
| —— | -$138K— | —— | —— | $138K— | ||
| $33K-2.9% | $34K+6.3% | $32K-3.0% | $33K0.0% | $33K0.0% | ||
| -$112K— | —— | —— | —— | $239K— | ||
| -$5.75M— | $0+100% | -$2.96M-53.1% | -$1.93M+79.9% | -$9.63M+38.4% | ||
| $199K-31.6% | $291K-18.5% | $357K-29.9% | $509K-29.6% | $723K-30.6% | ||
| -$3K— | —— | -$51K-250% | $34K+362% | -$13K-1,400% | ||
| -$67K-458% | -$12K— | —— | -$204K-332% | $88K— | ||
| -$2.63M— | —— | —— | $2.86M+282% | $750K— | ||
| —— | $0— | $0— | $0— | $0— | ||
| $22M-8.3% | $24M-19.0% | $29.62M+4.9% | $28.25M-2.6% | $29M+108% | ||
| $33K-2.9% | $34K+6.3% | $32K-3.0% | $33K0.0% | $33K0.0% | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| -$131K— | —— | -$99K— | —— | -$134K— | ||
| $298K— | —— | $143K— | —— | $882K+1,777% | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| —— | —— | —— | —— | $442K— | ||
| -$21.19M-39.9% | -$15.15M+23.5% | -$19.8M+17.6% | -$24.04M-18.1% | -$20.35M-38.3% | ||
| -$21.19M-39.9% | -$15.15M+23.5% | -$19.8M+17.6% | -$24.04M-18.1% | -$20.35M-38.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Artiva Biotherapeutics, Inc. generate?
- Artiva Biotherapeutics, Inc. (ARTV) generated -$77.9M in operating cash flow over the trailing twelve months.
- What is Artiva Biotherapeutics, Inc.'s free cash flow?
- After $2.3M of capital expenditures, Artiva Biotherapeutics, Inc.'s free cash flow was -$80.2M over the trailing twelve months, down 31.6% year over year.
- Where does Artiva Biotherapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Artiva Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.